Major Advance in Healthy Longevity: Senolytics

12983 Views
Was this article interesting to you?
Posted in: Anti-aging, Senolytics

Scientific Sources

36% longer lifespan elderly mice?

Compared to mice who aged normally, those that started dasatinib-quercetin senolytic cocktail at age equivalent to 75 to 90 years in humans ended up living roughly 36% longer, and with better physical function. Late-life intervention producing dramatic lifespan extension plus healthspan improvement. TIME Magazine reported discovery.

Elderly people restore physical functionality?

Last quote indicates that elderly people may be able to restore physical functionality and live longer by purging their bodies of senescent cells. Not just slowing aging but actual functional restoration in already elderly individuals. Senescent cell removal rejuvenating intervention.

Senescent cell burden reduction?

Reducing senescent cell burden in our tissues may help maintain optimal function and reduce risk for disease. Senescent cells accumulate with age secreting inflammatory factors damaging surrounding tissues. Selective elimination (senolysis) removes these harmful cells improving tissue health.

Dasatinib-quercetin cocktail?

Dasatinib-quercetin senolytic cocktail used in landmark study. Combination targeting senescent cells for selective elimination. Dasatinib is tyrosine kinase inhibitor (cancer drug repurposed), quercetin is natural flavonoid. Synergistic senolytic effect when combined.

TIME Magazine transformation?

TIME Magazine has reported discovery that will likely transform medical practice. Major media recognition of senolytic research significance. Paradigm shift from treating individual diseases to addressing fundamental aging mechanisms. Revolutionary implications for medicine and healthy longevity.

  • 36% longer lifespan elderly mice dasatinib-quercetin
  • Equivalent to 75-90 years humans late-life intervention
  • Better physical function healthspan not just lifespan
  • TIME Magazine report transformative discovery
  • Elderly people functional restoration rejuvenation potential
  • Live longer lifespan extension
  • Purging senescent cells selective elimination
  • Senescent cell burden reduction tissue accumulation
  • Optimal function maintenance performance preservation
  • Disease risk reduction pathology prevention
  • Dasatinib-quercetin cocktail synergistic combination
  • Senolytic drugs selective cell elimination
  • Transform medical practice paradigm shift
  • Inflammatory factor secretion SASP reduction

Senolytic Healthy Longevity Protocol

Step 1: 36% Longer Lifespan Elderly Mice - Late-Life Intervention

Compared to mice who aged normally, those that started dasatinib-quercetin senolytic cocktail at age equivalent to 75 to 90 years in humans ended up living roughly 36% longer, and with better physical function. Late-life intervention (started when already elderly) producing dramatic lifespan extension plus healthspan improvement. Not prevention in youth but actual intervention in advanced age. Demonstrates senolytic efficacy even when treatment delayed until equivalent of human elderly age.

Step 2: TIME Magazine Transformative Discovery

TIME Magazine has reported discovery that will likely transform medical practice. Major mainstream media recognition of senolytic research significance signals paradigm shift. Quote: "Compared to mice who aged normally, those that started the dasatinib-quercetin [senolytic] cocktail at an age equivalent to 75 to 90 years in humans ended up living roughly 36% longer, and with better physical function." Revolutionary implications - not treating individual diseases but addressing fundamental aging mechanisms underlying multiple age-related pathologies simultaneously.

Step 3: Elderly People Restore Physical Functionality and Live Longer

Last quote indicates that elderly people may be able to restore physical functionality and live longer by purging their bodies of senescent cells. Not just slowing aging decline but actual functional restoration in already elderly individuals. Senescent cell removal as rejuvenating intervention reversing aspects of aging rather than merely preventing progression. Physical functionality restoration includes: improved mobility, strength, endurance, coordination - practical daily living improvements not just laboratory biomarkers.

Step 4: Senescent Cell Burden and SASP

Reducing senescent cell burden in our tissues may help maintain optimal function and reduce risk for disease. Senescent cells accumulate with age in various tissues. No longer divide but don't die - persist in zombie-like state. Secrete inflammatory factors, proteases, growth factors collectively called SASP (senescence-associated secretory phenotype) damaging surrounding healthy cells and tissues. Selective elimination (senolysis) removes these harmful cells improving tissue microenvironment and function.

Step 5: Dasatinib-Quercetin Synergistic Senolytic Cocktail

Dasatinib-quercetin senolytic cocktail used in landmark study achieving 36% lifespan extension in elderly mice. Combination targeting senescent cells for selective elimination through complementary mechanisms. Dasatinib is tyrosine kinase inhibitor (approved cancer drug being repurposed) - inhibits pro-survival pathways in senescent cells. Quercetin is natural flavonoid with multiple senolytic mechanisms. Synergistic senolytic effect when combined - each alone less effective than combination.

Step 6: Major Advance Healthy Longevity - Transform Medical Practice

TIME Magazine recognition: discovery will likely transform medical practice. Senolytic approach represents major advance in healthy longevity. 36% lifespan extension in elderly mice (75-90 years human equivalent) with improved physical function. Elderly people may restore functionality and live longer by purging senescent cells. Reducing senescent cell burden maintains optimal function, reduces disease risk. Dasatinib-quercetin combination pioneering this transformative therapeutic strategy addressing fundamental aging mechanisms.

  • Elderly individuals (75-90 years equivalent - 36% lifespan)
  • Age-related functional decline physical performance
  • Senescent cell accumulation tissue aging
  • Chronic inflammation from SASP
  • Reduced physical function mobility impairment
  • Disease risk elevated age-related pathologies
  • Seeking longevity lifespan extension
  • Healthspan optimization functional years
  • Cellular senescence burden accumulated damage
  • Late-life intervention candidates already elderly
  • Physical functionality restoration rejuvenation goals
  • Part of senolytic research cutting-edge therapy
  • Dasatinib contraindications (cancer drug - oncologist consult)
  • Bleeding disorders (dasatinib antiplatelet effects)
  • Quercetin high-dose caution (kidney disease - oxalate concern)
  • Pregnancy/breastfeeding (insufficient safety data)

TIME Magazine and LA Times - 36% Longer Lifespan Elderly Mice: TIME Magazine reported discovery that will likely transform medical practice. Compared to mice who aged normally, those that started dasatinib-quercetin senolytic cocktail at age equivalent to 75 to 90 years in humans ended up living roughly 36% longer, and with better physical function. Late-life intervention producing dramatic results. Elderly people may be able to restore physical functionality and live longer by purging senescent cells.

Citations: Available at: http://time.com/5333752/aging-drugs. Accessed August 6, 2018. Available at: http://www.latimes.com/science/sciencenow/la-sci-sn-anti-aging-cocktail-20180710-story.html. Accessed August 6, 2018. Major media coverage establishing senolytic research as transformative medical advance.

Cellular Senescence - When Bad Things Happen to Good Cells: Senescent cells accumulate with age - no longer divide but persist secreting inflammatory factors (SASP) damaging surrounding tissues. Reducing senescent cell burden may help maintain optimal function and reduce disease risk. Fundamental aging mechanism underlying multiple age-related pathologies.

Citation: Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729-40. Landmark review establishing cellular senescence as aging mechanism and therapeutic target.

Achilles' Heel of Senescent Cells - Transcriptome to Senolytic Drugs: Senescent cells have vulnerabilities (Achilles' heel) exploitable by senolytic drugs. Transcriptome analysis identified pro-survival pathways in senescent cells that can be targeted for selective elimination. Led to development of first-generation senolytics including dasatinib-quercetin combination.

Citation: Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-58. Foundational paper establishing senolytic drug development strategy.

Senolytics Improve Physical Function and Increase Lifespan in Old Age: Direct evidence that senolytics improve physical function and increase lifespan when administered in old age (equivalent to 75-90 years humans). 36% lifespan extension with better physical function. Published in Nature Medicine establishing clinical translation potential.

Citation: Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018. Definitive study demonstrating senolytic efficacy for both lifespan and healthspan in elderly mice.

Programmed Cell Death Context - Apoptosis Review: Senolytics work by inducing apoptosis (programmed cell death) selectively in senescent cells while sparing normal cells. Understanding apoptosis mechanisms essential for senolytic drug development. Senescent cells resist apoptosis through pro-survival pathway upregulation which senolytics overcome.

Citation: Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. Comprehensive apoptosis review providing mechanistic context for senolytic action.